ESC at a glance
At ESC Congress 2026, how will earlier patient identification, treatment timing and evolving care pathways reshape competition in cardiovascular medicine? The congress will highlight strategic questions across transthyretin amyloid cardiomyopathy (ATTR-CM), hypertrophic cardiomyopathy (HCM), anticoagulation, lipid management and cardiovascular inflammation, alongside AI-enabled diagnosis and risk assessment.
📅 Build your schedule around the topics that matter most.
📥 Download the ESC 2026_Preview_by_LucidQuest
Key Cardiovascular Treatment Trends at ESC Congress 2026
ATTR-CM: Eplontersen and CARDIO-TTRansform
CARDIO-TTRansform will test eplontersen efficacy and safety, including its use alongside stabiliser therapy, as competition moves toward earlier identification and treatment selection in ATTR-CM.
Hypertrophic Cardiomyopathy: ACACIA-HCM, Mavacamten and CIRRUS-HCM
ACACIA-HCM, five-year mavacamten data and CIRRUS-HCM could clarify how sarcomere-directed therapies develop across obstructive and non-obstructive hypertrophic cardiomyopathy.
Factor XI/XIa Inhibitors: Milvexian and Asundexian
LIBREXIA ACS and OCEANIC-STROKE will test whether milvexian and asundexian can establish defined roles within secondary-prevention pathways.
Lipid-Lowering Therapies: AMUNDSEN, VESALIUS-CV and VICTORION-CHALLENGE
AMUNDSEN, VESALIUS-CV and VICTORION-CHALLENGE will examine whether differentiation increasingly depends on earlier treatment, rapid LDL-C goal attainment and residual lipid risk.
Cardiovascular Inflammation: Pacibekitug and IL-6 Inhibition
TRANQUILITY will test whether pacibekitug can move IL-6 inhibition toward a clinically actionable cardiovascular treatment strategy.
Competitor and Industry Signals at ESC Congress 2026
AstraZeneca, Alnylam and Pfizer: ATTR-CM Diagnosis and Treatment
ATTR programming is increasingly centred on earlier recognition, diagnosis, monitoring and treatment implementation.
Amgen, Novartis and Daiichi Sankyo: Lipid Management Competition
Lipid strategies are moving toward earlier intervention, lipoprotein(a) [Lp(a)], treatment optimisation and residual cardiovascular risk.
Emerging Cardiovascular Pipeline: EDG-7500, HRS-5346, Lepodisiran and Ticalicibart
EDG-7500, HRS-5346, lepodisiran and ticalicibart add new competitive signals across hypertrophic cardiomyopathy and lipid lowering.
Artificial Intelligence and Machine Learning at ESC Congress 2026
AI in Cardiology: Earlier Detection and Clinical Decision Support
Sessions on hereditary transthyretin amyloidosis (ATTRv), preventive cardiology and cardiovascular imaging suggest AI is moving closer to patient identification and treatment decisions.
ORFAN-MAESTRIA: AI-Based Atrial Myopathy Detection
AI-based detection of atrial myopathy from routine cardiac CT will test whether algorithmic outputs can support cardioembolic-stroke prediction.
What We Are Watching After ESC Congress 2026
- Whether new ATTR-CM, HCM and FXI/XIa data provide clearer treatment positioning.
- Whether AI outputs prove actionable enough to change diagnostic work-up, risk stratification or treatment intensification.
Download the ESC Congress 2026 Preview Report
Download LucidQuest’s ESC Congress 2026 preview report for deeper analysis of emerging cardiovascular therapies, clinical developments and competitive signals.
📅 Build your schedule around the sessions that matter most.
📥 Download the ESC 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
